Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

1,325

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

March 10, 2023

Study Completion Date

February 20, 2025

Conditions
Meningitis
Interventions
BIOLOGICAL

NmCV-5

NmCV-5 is a pentavalent meningococcal (A, C, Y, W, X) polysaccharideconjugate vaccine composed of capsularpolysaccharides (PS) from Neisseria meningitidis serogroups A, C, Y, W, and X individually conjugated to a protein carrier, either mutant diphtheria toxoid (CRM197) or tetanus toxoid (TT).

BIOLOGICAL

MenACWY-TT

MenACWY-TT (the comparator meningococcal vaccine) is a WHO-PQ quadrivalent meningococcal (A, C, Y, W) polysaccharide-conjugate vaccine manufactured by Pfizer.

Trial Locations (1)

Unknown

Centre pour le Developpement des Vaccins du Mali, Bamako

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Emory University

OTHER